Operating leverage from completed capex
Expected: OngoingHIGH confidence
What: Major capex largely behind enabling margin expansion
“Major capex largely behind, operating leverage beginning to play out”
Biocon Ltd: Why Is It Outperforming Nifty 500?
ActiveWeak4w Streak
In Week of Mar 28, 2026, Biocon Ltd (Pharma - Formulators) is outperforming Nifty 500 with +5.2% relative strength. Fundamentals: Weak. On a 4-week streak.
PE: Mid ExpansionDanger Bubble
What's Happening
⚠️PE rising despite falling earnings — price running ahead of reality
👔Promoter stake down 6.2% this quarter
🌐FII stake increased 0.7% this quarter
🏛️DII accumulation — stake up 7.6%
💰Trading 89% above estimated fair value — significant premium
Earnings Acceleration Triggers
1. Operating leverage from completed capex
OngoingHIGH
2. Interest cost savings from debt reduction
FY27HIGH
3. Generics GLP-1 expansion in EU
OngoingMEDIUM
Key Risks
1. CRDMO segment challenges
MEDIUM2. Margin pressure from new facilities
MEDIUMKey Numbers
PAT Growth YoY
-164%
Inflection Down
Revenue YoY
+9%
Stable
Operating Margin
20.0%
0 bps YoY
PE Ratio
73.1
Current Price
₹370
Dividend Yield
0.14%
Fundamental Score
31/100
Weak
3Y PAT CAGR
+23%
Market Cap
60.0K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
Why Are Biocon Ltd's Earnings Accelerating?
Based on Q3 FY26 earnings • Updated Mar 7, 2026
Interest cost savings from debt reduction
Expected: FY27HIGH confidence
What: Annualized savings of ₹300 cr from FY27
“Interest balance sheet interest cost has already started coming down and as indicated earlier we should see annualized savings of approximately 300 crores from FY27”
Generics GLP-1 expansion in EU
Expected: OngoingMEDIUM confidence
What: Ongoing launches of generic liraglutide driving 24% YoY growth
“This performance was supported by an ongoing launches of generic liraglutide across EU markets and an improved performance in the generic formulations base business”
What Are the Key Risks for Biocon Ltd?
Earnings deceleration risks from management commentary
CRDMO segment challenges
MEDIUMTrigger: Customer-specific issues persist
Management view: Performance impacted by challenges at one manufacturing customer – transient and should normalize over time
Monitor: CRDMO revenue growth
Margin pressure from new facilities
MEDIUMTrigger: Slow ramp-up of new facilities
Management view: Margins reflect higher costs from recently commissioned facilities
Monitor: Generics EBITDA margin
What Is Biocon Ltd's Management Saying?
Key quotes from recent conference calls
“Major capex largely behind, operating leverage beginning to play out — Investor Presentation”
“Margin improvement in this quarter reflects better product and geography mix as well as operating leverage benefits as we continue to realize the benefits of economies of scale — Management”
“Oncology franchise (Abevmy®, Ogivri®) driving growth — Investor Presentation”
“Focus on sustainable growth, margin expansion and cashflow led value-creation — Investor Presentation”
What Is Biocon Ltd's Management Guidance?
Forward-looking targets from management for Next 2-4 quarters
Management Tone: CAUTIOUS
Key Milestones
• Operating leverage benefits
• Interest cost savings from FY27
• CRDMO normalization
How Fast Is Biocon Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +9% | +23% | Stable |
| PAT (Net Profit) | -164% | +23% | Inflection Down |
| OPM | 20.0% | 0 bps | Expanding |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Mar 7, 2026.
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Biocon Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Biocon Ltd's latest quarterly results?
Biocon Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -164.2% (inflecting downward)
- Revenue Growth YoY: +9.2%
- Operating Margin: 20.0% (expanding)
Is Biocon Ltd's profit growing or declining?
Biocon Ltd's profit is declining with an inflecting downward trend.
- PAT Growth YoY: -164.2% (latest quarter)
- PAT Growth QoQ: -139.1% (sequential)
- 3-Year PAT CAGR: +22.8%
- Trend: Inflecting downward — consistent growth pattern
What is Biocon Ltd's revenue growth trend?
Biocon Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +9.2%
- Revenue Growth QoQ: -2.9% (sequential)
- 3-Year Revenue CAGR: +23.1%
How is Biocon Ltd's operating margin trending?
Biocon Ltd's operating margin is expanding.
- Current OPM: 20.0%
- OPM Change YoY: 0.0% basis points
- OPM Change QoQ: +1.0% basis points
What is Biocon Ltd's 3-year profit and revenue CAGR?
Biocon Ltd's long-term compounding rates
- 3-Year Profit CAGR: +22.8%
- 3-Year Revenue CAGR: +23.1%
Is Biocon Ltd's growth accelerating or decelerating?
Biocon Ltd's earnings growth is inflecting downward with mixed signals on a sequential basis.
- YoY Acceleration: -180.0% bps
- Sequential Acceleration: -99.4% bps
What is Biocon Ltd's trailing twelve month (TTM) performance?
Biocon Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹629 Cr
- TTM PAT Growth: -47.3% YoY
- TTM Revenue: ₹17,000 Cr
- TTM Revenue Growth: +14.0% YoY
- TTM Operating Margin: 20.6%
Is Biocon Ltd overvalued or undervalued?
Biocon Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 73.1x
- Price-to-Book: 1.9x
What is Biocon Ltd's current PE ratio?
Biocon Ltd's current PE ratio is 73.1x.
- Current PE: 73.1x
- Market Cap: 60.0K Cr
- Dividend Yield: 0.14%
How does Biocon Ltd's valuation compare to its history?
Biocon Ltd's current PE is 73.1x.
- Current PE: 73.1x
- Valuation Assessment: Significantly Overvalued
What is Biocon Ltd's price-to-book ratio?
Biocon Ltd's price-to-book ratio is 1.9x.
- Price-to-Book (P/B): 1.9x
- Book Value per Share: ₹200
- Current Price: ₹370
Is Biocon Ltd a fundamentally strong company?
Biocon Ltd is rated Weak with a fundamental score of 31.1/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +9.2% (10% weight)
- PAT Growth YoY: -164.2% (10% weight)
- PAT Growth QoQ: -139.1% (10% weight)
- Margins expanding (10% weight)
Is Biocon Ltd debt free?
Biocon Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹17,000 Cr
What is Biocon Ltd's return on equity (ROE) and ROCE?
Biocon Ltd's return ratios over recent years
- FY2023: ROCE 6.0%
- FY2024: ROCE 6.0%
- FY2025: ROCE 6.0%
Is Biocon Ltd's cash flow positive?
Biocon Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹4,000 Cr
- Free Cash Flow (FCF): ₹4,000 Cr
- CFO/PAT Ratio: 284% (strong cash conversion)
What is Biocon Ltd's dividend yield?
Biocon Ltd's current dividend yield is 0.14%.
- Dividend Yield: 0.14%
- Current Price: ₹370
Who holds Biocon Ltd shares — promoters, FII, DII?
Biocon Ltd's shareholding pattern (Jan 2026)
- Promoters: 44.9%
- FII (Foreign): 7.1%
- DII (Domestic): 24.1%
- Public: 23.7%
Is promoter holding increasing or decreasing in Biocon Ltd?
Biocon Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 44.9% (Jan 2026)
- Previous Quarter: 54.5% (Dec 2025)
- Change: -9.54% (decreasing — worth monitoring)
How long has Biocon Ltd been outperforming Nifty 500?
Biocon Ltd has been outperforming Nifty 500 for 4 consecutive weeks, indicating building momentum.
Is Biocon Ltd a new momentum entry or an established outperformer?
Biocon Ltd is an established outperformer with 4 weeks of consecutive Nifty 500 outperformance.
What are the growth catalysts for Biocon Ltd?
Biocon Ltd has 3 key growth catalysts identified from recent earnings analysis
- Operating leverage from completed capex
- Interest cost savings from debt reduction
- Generics GLP-1 expansion in EU
What are the key risks in Biocon Ltd?
Biocon Ltd has 2 key risks worth monitoring
- CRDMO segment challenges
- Margin pressure from new facilities
What did Biocon Ltd's management say in the latest earnings call?
In Q3 FY26, Biocon Ltd's management highlighted
- "Major capex largely behind, operating leverage beginning to play out — Investor Presentation"
- "Margin improvement in this quarter reflects better product and geography mix as well as operating leverage benefits as we continue to realize the bene..."
- "Oncology franchise (Abevmy®, Ogivri®) driving growth — Investor Presentation"
What is Biocon Ltd's management guidance for growth?
Biocon Ltd's management has provided the following forward guidance for Next 2-4 quarters
- Management tone: cautious
- Milestone: Operating leverage benefits
- Milestone: Interest cost savings from FY27
Is Biocon Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Biocon Ltd may be worth studying
- Operating margins are expanding — OPM at 20.0%
- Cash flow is positive — CFO ₹4,000 Cr
What is the investment thesis for Biocon Ltd?
Biocon Ltd investment thesis summary:
Research Signals (Bull Case)
- Margins expanding
- Growth catalyst: Operating leverage from completed capex
Risk Factors (Bear Case)
- Appears significantly overvalued
- Key risk: CRDMO segment challenges
What is the future outlook for Biocon Ltd?
Biocon Ltd's forward outlook based on current data signals
- Earnings Trend: inflecting downward
- Revenue Trend: stable
- Margin Trend: expanding
- Valuation: Significantly Overvalued
- Key Catalyst: Operating leverage from completed capex
- Key Risk: CRDMO segment challenges
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.